Navigation Links
OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences

BOTHELL, WA and VANCOUVER, Sept. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company will webcast presentations at the following investor conferences:

    -   Rodman & Renshaw 11th Annual Healthcare Conference on Thursday,
        September 10, 2009 at 12:30 p.m. Eastern Time in the Fahnestock Salon
        at the New York Palace Hotel in New York City.

    -   Thomas Weisel Partners Healthcare Conference on Friday, September 11,
        2009 at 10:20 a.m. Eastern Time in the Stuart Room at the Four
        Seasons Hotel in Boston.

    -   BioCentury NewsMakers in the Biotech Industry Conference on
        Wednesday, September 16, 2009 at 2:30 p.m. Eastern Time in room
        304/305 at the Millennium Broadway Hotel & Conference Center in New
        York City.

Access to a live webcast of each of the presentations will be available on the Events Presentation section of the Investor Relations page on the company Web site at A replay of each webcast will be available for 30 days following the event.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical develo

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
(Date:7/31/2014)... SoundConnect , an award winning ... to announce the addition of Adobe Connects Learning ... tools to quickly deploy and manage online courses ... for desktop and mobile learning solutions. , Adobe ... online training solution, enabling organizations to deploy, measure, ...
(Date:7/30/2014)... 30, 2014 Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting microRNAs, ... highlights for the quarter ended June 30, 2014 on ... close. Regulus will host a conference ... 5:00 pm Eastern Daylight Time to discuss its second ...
(Date:7/30/2014)... 30, 2014 A study presented at ... and efficacy of CSL Behring,s C1 Inhibitor (C1-INH) ... in highly sensitized patients. C1-INH is a human ... system. The study shows that post-transplant ... the levels of complement components 3 and 4, ...
(Date:7/30/2014)... Selexis SA , a serial ... and mammalian cell line development, announced today new data ... be presented at the 10th Annual Cell Line ... – 10, 2014 at the Double Tree by Hilton ... abstract will be presented during an oral presentation: , ...
Breaking Biology Technology:SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3
... Medco Health,Solutions, Inc. (NYSE: MHS ) Chairman ... members of his senior management team, will present an,overview ... and institutional investors during its annual Analyst Day,conference on ... of Pharmacy," is scheduled to begin at 8 a.m. ...
... Abercrombie, Pfizer R&D Head Martin,Mackay, HHS Deputy Secretary Tevi ... Agenda at FDA/CMS Summit 2007, WASHINGTON, Nov. 15 ... drug approvals. Unfortunately for the biopharma sector and,investors, it,s ... on track,to grant marketing approval to 18 or fewer ...
... Brad Thompson, President,and CEO of Oncolytics Biotech Inc. ... of the company at Toronto CFA Society on ... at the National Club, 303 Bay,Street, Toronto at ... Oncolytics is a Calgary-based biotechnology company focused on ...
Cached Biology Technology:Medco to Webcast Annual Analyst Day Conference 2So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 2So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 3Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society 2
(Date:7/30/2014)... a massive collection of 20-million-year-old amber found in the ... effort is yielding fresh insights into ancient tropical insects ... is fully curated, a task that will take many ... collection in the world, the researchers report. , ... of a pygmy locust, a tiny grasshopper the size ...
(Date:7/30/2014)... of Engineering recently received a $330,000 award from ... synthesis of organic nanorods." , According to ... and utilization of functional materials, devices, and systems ... in scaling up nanotechnology is the lack of ... one device. A research team led by Dr. ...
(Date:7/30/2014)... Wallerian degeneration is a subject of major interest ... differentially regulated during the distinct stages of Wallerian ... differentiation and dedifferentiation. Although gene expression responses in ... peripheral nerve injury are known, differences in gene ... unclear. Dr. Dengbing Yao and co-workers from Nantong ...
Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... ON (September 05, 2011) You may think your lack ... because you,re lazy, but McMaster University researchers have discovered it ... made their unexpected finding while working with healthy, specially-bred mice, ... exercise removed. The genes control the protein AMP-activated protein kinase ...
... It is now widely accepted that the species Homo ... world. But did those early humans interbreed with more ... erectus, the "upright walking man," Homo habilis, the ... cave-painting fame? Direct studies of ancient DNA from ...
... Ten variants of the deadly Escherichia coli ... sequenced across the world. The unprecedented level of collaboration ... the outbreak arose, says a scientist at the Society ... the bacterium started in early June at BGI, China. ...
Cached Biology News:McMaster researchers find missing genes may separate coach potato from active cousin 2Ancient humans were mixing it up 2Ancient humans were mixing it up 3Ancient humans were mixing it up 4Crowd-sourcing the E. coli O104:H4 outbreak 2
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
... This reagent has been developed ... for the reduction of nonspecific background ... Traditional methods describe blocking peroxidase with ... hydrogen peroxide in combination with additional ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Biology Products: